First Synthesis of 3-Amino-2-arylimidazo[1,2-b]pyridazines by Groebke-Blackburn
Reaction

Clemens Lamberth

doi:10.1055/s-0030-1260940

LETTER

First Synthesis of 3-Amino-2-arylimidazo[1,2-b]pyridazines by Groebke-Blackburn Reaction

Clemens Lamberth*
Syngenta Crop Protection AG, Research Chemistry, Schaffhauserstr. 101, 4332 Stein, Switzerland
Fax: +41(62)8660860; e-Mail: clemens.lamberth@syngenta.com;

Abstract

Alle Artikel dieser Rubrik

Abstract

The Groebke-Blackburn transformation of an 3-aminopyridazine, a benzaldehyde, and an isocyanide allows the one-step assembly of so far unknown 3-amino-2-arylimidazo[1,2-b]-pyridazines. Diversely substituted aldehydes and isocyanides can be used for this reliable three-component condensation, delivering biheterocyclic products with a broad range of different substituents in the imidazole moiety.

Key words

multicomponent reaction - Groebke-Blackburn reaction - heterocycles - imidazopyridazines - ring closure

Volltext

Referenzen

References and Notes

<A NAME="RB06811ST-1A">1a</A> Dömling A. Chem. Rev. 2006, 106: 17

<A NAME="RB06811ST-1B">1b</A> Multicomponent Reactions Zhu J. Bienayme H. Wiley-VCH; Weinheim: 2005.

<A NAME="RB06811ST-2A">2a</A> Synthesis of Heterocycles via Multicomponent Reactions, In Top. Heterocycl. Chem. Orru R. V. A., Ruijter E. Vol. 23: Springer; Berlin: 2010.

<A NAME="RB06811ST-2B">2b</A> Jiang B. Shi F. Tu S.-J. Curr. Org. Chem. 2010, 14: 357

<A NAME="RB06811ST-2C">2c</A> Jiang B. Rajale T. Wever W. Tu S.-J. Li G. Chem. Asian J. 2010, 5: 2318

<A NAME="RB06811ST-2D">2d</A> Ivachtchenko AV. Ivanenkov YA. Kysil VM. Krasavin MY. Ilyin AP. Russ. Chem. Rev. 2010, 79: 787

<A NAME="RB06811ST-2E">2e</A> Sunderhaus JD. Martin SF. Chem. Eur. J. 2009, 15: 1300

<A NAME="RB06811ST-2F">2f</A> D’Souza DM. Müller TJJ. Chem. Soc. Rev. 2007, 36: 1095

<A NAME="RB06811ST-3A">3a</A> Groebke K. Weber L. Mehlin F. Synlett 1998, 661

<A NAME="RB06811ST-3B">3b</A> Blackburn C. Guan B. Fleming P. Shiosaki K. Tsai S. Tetrahedron Lett. 1998, 39: 3635

<A NAME="RB06811ST-3C">3c</A> Bienayme H. Bouzid K. Angew. Chem. Int. Ed. 1998, 37: 2234 ; Angew. Chem. 1998, 110, 2349

<A NAME="RB06811ST-4A">4a</A> Li L. Hopkinson MN. Yona RL. Bejot R. Gee AD. Gouverneur V. Chem. Sci. 2011, 2: 123

<A NAME="RB06811ST-4B">4b</A> Odell LR. Nilsson MT. Gising J. Lagerlund O. Muthas D. Nordqvist A. Karlen A. Larhed M. Bioorg. Med. Chem. Lett. 2009, 19: 4790

<A NAME="RB06811ST-4C">4c</A> Lacerda RB. de Lima CKF. da Silva LL. Romeiro NC. Miranda ALP. Barreiro EJ. Fraga CAM. Bioorg. Med. Chem. 2009, 17: 74

<A NAME="RB06811ST-4D">4d</A> Shaabani A. Soleimani E. Sarvary A. Rezayan AH. Maleki A. Chin. J. Chem. 2009, 27: 369

<A NAME="RB06811ST-4E">4e</A> Rousseau AL. Matlaba P. Parkinson CJ. Tetrahedron Lett. 2007, 48: 4079

<A NAME="RB06811ST-4F">4f</A> Shaabani A. Maleki A. Rad JM. Soleimani E. Chem. Pharm. Bull. 2007, 55: 957

<A NAME="RB06811ST-4G">4g</A> Shaabani A. Soleimani E. Maleki A. Tetrahedron Lett. 2006, 47: 3031

<A NAME="RB06811ST-4H">4h</A> Chen JJ. Golebiowski A. McClenaghan J. Klopfenstein SR. West L. Tetrahedron Lett. 2001, 42: 2269

<A NAME="RB06811ST-5A">5a</A> Shaabani A. Rezazadeh F. Soleimani E. Monatsh. Chem. 2008, 139: 931

<A NAME="RB06811ST-5B">5b</A> Shaabani A. Soleimani E. Maleki A. Moghimi-Rad J. Synth. Commun. 2008, 38: 1090

<A NAME="RB06811ST-5C">5c</A> Sandulenko Y. Komarov A. Rufanov K. Krasavin M. Tetrahedron Lett. 2008, 49: 5990

<A NAME="RB06811ST-5D">5d</A> Varma RS. Kumar D. Tetrahedron Lett. 1999, 40: 7665

<A NAME="RB06811ST-5E">5e</A> Blackburn C. Tetrahedron Lett. 1998, 39: 5469

<A NAME="RB06811ST-6">6</A> Al-Tel TH. Al-Qawasmeh RA. Voelter W. Eur. J. Org. Chem. 2010, 5586

<A NAME="RB06811ST-7">7</A> Krasavin M. Tsirulnikov S. Nikulnikov M. Sandulenko Y. Bukhryakov K. Tetrahedron Lett. 2008, 49: 7318

<A NAME="RB06811ST-8">8</A> Guchhait SK. Maadan C. Synlett 2009, 628

<A NAME="RB06811ST-9">9</A> Guchhait SK. Maadan C. Thakkar BS. Synthesis 2009, 3293

<A NAME="RB06811ST-10A">10a</A> Guchhait SK. Madaan C. Org. Biomol. Chem. 2010, 8: 3631

<A NAME="RB06811ST-10B">10b</A> Ireland SM. Tye H. Whittaker M. Tetrahedron Lett. 2003, 44: 4369

<A NAME="RB06811ST-11">11</A> Polyakov AI. Eryomina VA. Medvedeva LA. Tihonova NI. Voskressensky LG. J. Heterocycl. Chem. 2008, 45: 1589

<A NAME="RB06811ST-12">12</A> Krasavin M. Tsirulnikov S. Nikulnikov M. Kysil V. Ivachtchenko A. Tetrahedron Lett. 2008, 49: 5241

<A NAME="RB06811ST-13">13</A> Parchinsky VZ. Koleda VV. Shuvalova O. Kravchenko DV. Krasavin M. Tetrahedron Lett. 2006, 47: 6891

<A NAME="RB06811ST-14">14</A> Tsirulnikov S. Kysil V. Ivachtchenko A. Krasavin M. Synth. Commun. 2010, 40: 111

<A NAME="RB06811ST-15A">15a</A> Zhou T. Commodore L. Huang W.-S. Wang Y. Thomas M. Keats J. Xu Q. Rivera VM. Shakespeare WC. Clackson T. Dalgarno DC. Zhu X. Chem. Biol. Drug Des. 2011, 77: 1

<A NAME="RB06811ST-15B">15b</A> Huang W.-S. Metcalf CA. Sundaramoorthi R. Wang Y. Zou D. Thomas RM. Zhu X. Cai L. Wen D. Liu S. Romero J. Qi J. Chen I. Banda G. Lentini SP. Das S. Xu Q. Keats J. Wang F. Wardwell S. Ning Y. Snodgrass JT. Broudy MI. Russian K. Zhou T. Commodore L. Narasimhan NI. Mohemmad QK. Iuliucci J. Rivera VM. Dalgarno DC. Sawyer TK. Clackson T. Shakespeare WC. J. Med. Chem. 2010, 53: 4701

<A NAME="RB06811ST-16A">16a</A> Fukuda S. Midoro K. Yamasaki M. Gyoten M. Kawano Y. Fukui H. Ashida Y. Nagaya H. Inflammation Res. 2003, 52: 206

<A NAME="RB06811ST-16B">16b</A> Fukuda S. Midoro K. Kamei T. Gyoten M. Kawano Y. Ashida Y. Nagaya H. J. Pharmacol. Exp. Ther. 2002, 303: 1283

<A NAME="RB06811ST-17">17</A> Bouloc N. Large JM. Smiljanic E. Whalley D. Ansell KH. Edlin CD. Bryans JS. Bioorg. Med. Chem. Lett. 2008, 18: 5294

<A NAME="RB06811ST-18">18</A> Hamdouchi C. Sanchez-Martinez C. Gruber J. del Prado M. Lopez J. Rubio A. Heinz BA. J. Med. Chem. 2003, 46: 4333

<A NAME="RB06811ST-19">19</A> Russell MGN. Carling RW. Street LJ. Hallett DJ. Goodacre S. Mezzogori E. Reader M. Cook SM. Bromidge FA. Newman R. Smith AJ. Wafford KA. Marshall GR. Reynolds DS. Dias R. Ferris P. Stanley J. Lincoln R. Tye SJ. Sheppard WFA. Sohal B. Pike A. Dominguez M. Atack JR. Castro JL. J. Med. Chem. 2006, 49: 1235

<A NAME="RB06811ST-20">20</A> Zeng F. Alagille D. Tamagnan GD. Ciliax BJ. Levey AI. Goodman MM. ACS Med. Chem. Lett. 2010, 1: 80

<A NAME="RB06811ST-21A">21a</A> Lamberth C. Jeanguenat A. Cederbaum F. De Mesmaeker A. Zeller M. Kempf H.-J. Zeun R. Bioorg. Med. Chem. 2008, 16: 1531

<A NAME="RB06811ST-21B">21b</A> Lamberth C. Kempf H.-J. Kriz M. Pest Manag. Sci. 2007, 63: 57

<A NAME="RB06811ST-21C">21c</A> Lamberth C. Cederbaum F. Jeanguenat A. Kempf H.-J. Zeller M. Zeun R. Pest Manag. Sci. 2006, 62: 446

<A NAME="RB06811ST-21D">21d</A> Cederbaum F. De Mesmaeker A. Jeanguenat A. Kempf H.-J. Lamberth C. Schnyder A. Zeller M. Zeun R. Chimia 2003, 57: 680

Representative Procedure
tert-Butyl isocyanide (4a, 200 mg, 2.4 mmol), benzaldehyde (5a, 233 mg, 2.2 mmol), and 3-amino-6-chloropyridazine (3, 260 mg, 2.0 mmo) are consecutively added to a solution of NH₄Cl (107 mg, 2.0 mmol) in MeOH (10 mL). The reaction mixture is stirred for 16 h at r.t. Subsequently, the solvent was removed in vacuo and the remainder taken up in EtOAc. This organic layer was washed with brine and H₂O, dried over Na₂SO₄ and evaporated. The residue was purified either by crystallization from Et₂O or by chromatography on silica gel, using cyclohexane-EtOAc (4:1) as eluent to deliver
3-tert-butylamino-6-chloro-2-phenylimidazo[1,2-b]pyrida-zine as yellow crystals (6a, 500 mg, 1.7 mmol, 83%); mp 219-222 ˚C. ^¹H NMR (400 MHz, CDCl₃): δ = 1.13 (s, 9 H), 3.44 (br s, 1 H), 6.95 (d, 1 H), 7.32 (t, 1 H), 7.43 (t, 2 H), 7.80 (d, 1 H), 8.22 (d, 2 H) ppm. LC-MS: t _R = 1.93 min, m/z = 301 [M + 1].

<A NAME="RB06811ST-23A">23a</A> Fayol A. Zhu J. Org. Lett. 2004, 6: 115

<A NAME="RB06811ST-23B">23b</A> Fayol A. Zhu J. Angew. Chem. Int. Ed. 2002, 41: 3633 ; Angew. Chem. 2002, 114, 3785

<A NAME="RB06811ST-23C">23c</A> Janvier P. Sun X. Bienayme H. Zhu J. J. Am. Chem. Soc. 2002, 124: 2560

Further Spectroscopic Data Compound 6b: ^¹H NMR (400 MHz, CDCl₃): δ = 0.89 (t, 3 H), 1.38 (q, 2 H), 1.57 (q, 2 H), 3.15 (q, 2 H), 3.99 (t, 1 H), 6.85 (d, 1 H), 7.32 (t, 1 H), 7.44 (t, 2 H), 7.78 (d, 1 H), 8.03 (d, 2 H) ppm. LC-MS: t _R = 2.05 min, m/z = 301 [M + 1].
Compound 6c: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12-1.89 (m, 10 H), 3.22 (q, 1 H), 3.89 (d, 1 H), 6.87 (d, 1 H), 7.32 (t, 1 H), 7.44 (t, 2 H), 7.78 (d, 1 H), 8.10 (d, 2 H) ppm. LC-MS: t _R = 2.15 min, m/z = 327 [M + 1].
Compound 6d: ^¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 6 H), 2.20 (s, 3 H), 2.73 (s, 2 H), 3.96 (br s, 1 H), 6.96 (d, 1 H), 7.33 (t, 1 H), 7.42 (t, 2 H), 7.80 (d, 1 H), 8.21 (d, 2 H) ppm. LC-MS: t _R = 2.04 min, m/z = 347 [M + 1].
Compound 6e: ^¹H NMR (400 MHz, CDCl₃): δ = 1.03 (s, 6 H), 1.10 (s, 9 H), 1.18 (s, 2 H), 3.56 (br s, 1 H), 6.91 (d, 1 H), 7.31 (t, 1 H), 7.42 (t, 2 H), 7.78 (d, 1 H), 8.17 (d, 2 H) ppm. LC-MS: t _R = 2.32 min, m/z = 357 [M + 1].
Compound 6f: ^¹H NMR (400 MHz, CDCl₃): δ = 5.88 (br s, 1 H), 6.55 (d, 1 H), 6.64 (s, 1 H), 6.72-6.79 (m, 2 H), 7.05 (d, 1 H), 7.29-7.56 (m, 4 H), 7.91 (d, 1 H), 8.10 (d, 2 H) ppm. LC-MS: t _R = 1.89 min, m/z = 361 [M + 1].
Compound 6g: ^¹H NMR (400 MHz, CDCl₃): δ = 2.01 (s, 6 H), 5.69 (br s, 1 H), 6.81-6.93 (m, 4 H), 7.14-7.20 (m, 3 H), 7.58 (dd, 2 H), 7.82 (d, 1 H) ppm. LC-MS: t _R = 2.03 min, m/z = 349 [M + 1].
Compound 6h: ^¹H NMR (400 MHz, CDCl₃): δ = 4.30-4.39 (m, 3 H), 6.87 (d, 1 H), 7.19-7.36 (m, 6 H), 7.47 (t, 2 H), 7.78 (d, 1 H), 8.01 (d, 2 H) ppm. LC-MS: t _R = 1.98 min, m/z = 335 [M + 1].
Compound 6i: ^¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 9 H), 3.46 (br s, 1 H), 6.99 (d, 1 H), 7.52-7.83 (m, 4 H), 8.47 (d, 1 H), 8.66 (d, 1 H) ppm. LC-MS: t _R = 2.19 min, m/z = 369 [M + 1].
Compound 6j: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.43 (br s, 1 H), 6.97 (d, 1 H), 7.21-7.28 (m, 2 H), 7.80 (d, 1 H), 8.30 (d, 2 H) ppm. LC-MS: t _R = 2.20 min, m/z = 385 [M + 1].
Compound 6k: ^¹H NMR (400 MHz, CDCl₃): δ = 1.13 (s, 9 H), 2.31 (s, 3 H), 3.40 (br s, 1 H), 6.95 (d, 1 H), 7.22 (t, 1 H), 7.79 (d, 1 H), 7.92-7.98 (m, 2 H) ppm. LC-MS: t _R = 2.14 min, m/z = 333 [M + 1].
Compound 6l: ^¹H NMR (400 MHz, CDCl₃): δ = 1.16 (s, 9 H), 3.42 (br s, 1 H), 6.98 (d, 1 H), 7.43 (t, 1 H), 7.80 (d, 1 H), 8.03 (d, 1 H), 8.15 (d, 1 H) ppm. LC-MS: t _R = 2.23 min,
m/z = 353 [M + 1].
Compound 6m: ^¹H NMR (400 MHz, CDCl₃): δ = 1.04 (s, 9 H), 3.58 (br s, 1 H), 3.95 (s, 3 H), 6.88-7.04 (m, 2 H), 7.20 (t, 1 H), 7.39 (t, 1 H), 7.82 (d, 1 H) ppm. LC-MS: t _R = 1.92 min, m/z = 349 [M + 1].
Compound 6n: ^¹H NMR (400 MHz, CDCl₃): δ = 1.07 (s, 9 H), 3.58 (br s, 1 H), 3.96 (s, 3 H), 7.00 (d, 1 H), 7.27 (s, 1 H), 7.48 (d, 1 H), 7.83 (d, 1 H) ppm. LC-MS: t _R = 2.07 min, m/z = 383 [M + 1].
Compound 6o: ^¹H NMR (400 MHz, CDCl₃): δ = 1.04 (s, 9 H), 3.49 (br s, 1 H), 6.03 (s, 2 H), 6.95-7.00 (m, 2 H), 7.06 (s, 1 H), 7.81 (d, 1 H) ppm. LC-MS: t _R = 1.98 min, m/z = 379 [M + 1].
Compound 7: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.33 (br s, 1 H), 3.48 (s, 3 H), 3.80 (t, 2 H), 4.49 (t, 2 H), 6.63 (d, 1 H), 7.28 (t, 1 H), 7.41 (t, 2 H), 7.72 (d, 1 H), 8.23 (d, 2 H) ppm. LC-MS: t _R = 1.58 min, m/z = 341 [M + 1].
Compound 8: ^¹H NMR (400 MHz, CDCl₃): δ = 3.75 (br s, 1 H), 7,11 (dd, 1 H), 6.95 (d, 1 H), 7.33 (t, 1 H), 7.45 (t, 2 H), 7.82-7.88 (m, 2 H), 7.97 (d, 1 H), 8.22 (d, 2 H) ppm.
LC-MS: t _R = 1.89 min, m/z = 355 [M + 1].
Compound 9: ^¹H NMR (400 MHz, CDCl₃): δ = 1.15 (s, 9 H), 3.45 (t, 4 H), 3.72 (t, 4 H), 3.51 (br s, 1 H), 6.89 (d, 1 H), 7.31 (t, 1 H), 7.43 (t, 2 H), 7.82 (d, 1 H), 8.26 (d, 2 H) ppm.
LC-MS: t _R = 1.77 min, m/z = 352 [M + 1].
Compound 10: ^¹H NMR (400 MHz, CDCl₃): δ = 4.41 (br s, 2 H), 6.83 (t, 1 H), 7.32 (t, 1 H), 7.40-7.52 (m, 2 H), 7.76 (t, 1 H), 7.92 (t, 2 H) ppm. LC-MS: t _R = 1.46 min, m/z = 245
[M + 1].
Compound 11: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.56 (br s, 1 H), 3.77 (s, 6 H), 5.80 (s, 1 H), 7.31 (t, 2 H), 7.44 (t, 2 H), 7.82 (d, 1 H), 8.29 (d, 2 H) ppm. LC-MS: t _R = 2.12 min, m/z = 437 [M + 1].
Compound 12: ^¹H NMR (400 MHz, CDCl₃): δ = 1.18 (t, 3 H), 2.74 (q, 2 H), 3.56 (br s, 1 H), 6.97 (d, 1 H), 7.33 (t, 1 H), 7.40-7.48 (m, 2 H), 7.80 (d, 1 H), 8.30 (d, 2 H) ppm.
LC-MS: t _R = 1.67 min, m/z = 337 [M + 1].